Lauren C Harshman MD
Lauren C Harshman MD
Unknown affiliation
Verified email at
Cited by
Cited by
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
DYC Heng, W Xie, MM Regan, LC Harshman, GA Bjarnason, ...
The lancet oncology 14 (2), 141-148, 2013
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
VA Adalsteinsson, G Ha, SS Freeman, AD Choudhury, DG Stover, ...
Nature communications 8 (1), 1324, 2017
Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
AKA Lalani, W Xie, DJ Martini, JA Steinharter, CK Norton, KM Krajewski, ...
Journal for immunotherapy of cancer 6, 1-9, 2018
The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients
PS Hall, LC Harshman, S Srinivas, RM Witteles
JACC: Heart Failure 1 (1), 72-78, 2013
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle‐invasive bladder cancer
MD Galsky, SK Pal, S Chowdhury, LC Harshman, SJ Crabb, YN Wong, ...
Cancer 121 (15), 2586-2593, 2015
Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey
SL Chang, LC Harshman, JC Presti Jr
Journal of clinical oncology 28 (25), 3951, 2010
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study
NM Chanzá, W Xie, MA Bilen, H Dzimitrowicz, J Burkart, DM Geynisman, ...
The Lancet Oncology 20 (4), 581-590, 2019
Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer
LC Harshman, X Wang, M Nakabayashi, W Xie, L Valenca, L Werner, ...
JAMA oncology 1 (4), 495-504, 2015
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study
LC Harshman, W Xie, GA Bjarnason, JJ Knox, M MacKenzie, L Wood, ...
The lancet oncology 13 (9), 927-935, 2012
Results of a multicenter phase II study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and/or sarcomatoid features
BA McGregor, RR McKay, DA Braun, L Werner, K Gray, A Flaifel, ...
Journal of Clinical Oncology 38 (1), 63, 2020
Comparative effectiveness of trimodal therapy versus radical cystectomy for localized muscle-invasive urothelial carcinoma of the bladder
T Seisen, M Sun, SR Lipsitz, F Abdollah, JJ Leow, M Menon, MA Preston, ...
European urology 72 (4), 483-487, 2017
Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)
E Francini, KP Gray, W Xie, GK Shaw, L Valença, B Bernard, L Albiges, ...
The Prostate 78 (12), 889-895, 2018
Tumor fraction in cell-free DNA as a biomarker in prostate cancer
AD Choudhury, L Werner, E Francini, XX Wei, G Ha, SS Freeman, ...
JCI insight 3 (21), 2018
Mutational analysis of 472 urothelial carcinoma across grades and anatomic sites
AH Nassar, R Umeton, J Kim, K Lundgren, L Harshman, EM Van Allen, ...
Clinical Cancer Research 25 (8), 2458-2470, 2019
The clinical activity of PD-1/PD-L1 inhibitors in metastatic non–clear cell renal cell carcinoma
RR McKay, D Bossé, W Xie, SAM Wankowicz, A Flaifel, R Brandao, ...
Cancer immunology research 6 (7), 758-765, 2018
Evaluation of intense androgen deprivation before prostatectomy: a randomized phase II trial of enzalutamide and leuprolide with or without abiraterone
RR McKay, H Ye, W Xie, R Lis, C Calagua, Z Zhang, QD Trinh, SL Chang, ...
Journal of Clinical Oncology 37 (11), 923, 2019
Adjuvant vascular endothelial growth factor–targeted therapy in renal cell carcinoma: a systematic review and pooled analysis
M Sun, L Marconi, T Eisen, B Escudier, RH Giles, NB Haas, LC Harshman, ...
European urology 74 (5), 611-620, 2018
Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma
Z Bakouny, DA Braun, SA Shukla, W Pan, X Gao, Y Hou, A Flaifel, S Tang, ...
Nature communications 12 (1), 808, 2021
First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC
JJ Ko, TK Choueiri, BI Rini, JL Lee, N Kroeger, S Srinivas, LC Harshman, ...
British journal of cancer 110 (8), 1917-1922, 2014
Elevated IL‐8, TNF‐α, and MCP‐1 in men with metastatic prostate cancer starting androgen‐deprivation therapy (ADT) are associated with shorter time to castration‐resistance and …
J Sharma, KP Gray, LC Harshman, C Evan, M Nakabayashi, R Fichorova, ...
The Prostate 74 (8), 820-828, 2014
The system can't perform the operation now. Try again later.
Articles 1–20